STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
AI Summary
Tango Therapeutics reported that an experimental drug combination produced tumor responses in 82% of patients with a subtype of advanced pancreatic cancer. The results are from a clinical trial, though further details about the study were not provided.
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
Health pancreatic cancer Tango Therapeutics clinical trial combination therapy tumor response experimental drug